Breast cancer‐derived K172N, D301V mutations abolish Na<sup>+</sup>/H<sup>+</sup> exchanger regulatory factor 1 inhibition of platelet‐derived growth factor receptor signaling
Shan Cheng(Capital Medical University), Junqi He(Qingdao University), Shuai Zheng(Capital Medical University), Longyan Yang(Beijing Luhe Hospital Affiliated to Capital Medical University), Qian Ma(Memorial Sloan Kettering Cancer Center), Shuhui Wang(Capital Medical University), Ran Meng(Hefei University of Technology), Songlin Wang(Sun Yat-sen University), Duiping Feng(Shanxi Medical University), Ying Yang(Guiyang Medical University), Wen G. Jiang(Shandong Center for Disease Control and Prevention), Yang Li(Anhui Medical University)
Cited by 18
Related Papers
Phase separation of OCT4 controls TAD reorganization to promote cell fate transitions
|Cell stem cell|2021|159
Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development
|Journal of Medicinal Chemistry|2014|151
Proteomic Analysis of β1-Adrenergic Receptor Interactions with PDZ Scaffold Proteins
|Journal of Biological Chemistry|2005|134
The mRNA expression of SATB1 and SATB2 in human breast cancer
|Cancer Cell International|2009|103